资料显示，江苏硕世生物科技股份有限公司位于江苏省泰州市药城大道837号，成立日期2010年4月12 日，上市日期2019年12月5日，公司主营业务涉及体外诊断试剂、配套检测仪器等体外诊断产品的研 发、生产和销售。主营业务收入构成为：检测试剂85.89%，外购仪器及材料7.19%，检测仪器3.84%， 检测服务2.24%，其他0.84%。 硕世生物所属申万行业为：医药生物-医疗器械-体外诊断。所属概念板块包括：高派息、增持回购、小 盘、融资融券、抗流感等。 10月30日，硕世生物盘中下跌2.01%，截至10:12，报75.73元/股，成交4534.44万元，换手率0.71%，总 市值63.52亿元。 资金流向方面，主力资金净流出340.27万元，特大单买入147.41万元，占比3.25%，卖出115.05万元，占 比2.54%；大单买入1205.37万元，占比26.58%，卖出1577.99万元，占比34.80%。 硕世生物今年以来股价涨84.68%，近5个交易日涨0.46%，近20日涨15.44%，近60日涨43.48%。 今年以来硕世生物已经1次登上龙虎榜，最近一次登上龙虎榜为2月17日，当日龙虎榜净买入1 ...

江苏硕世生物科技股份有限公司 2025 年第二次临时股东大会会议材料 证券简称：硕世生物 证券代码：688399 江苏硕世生物科技股份有限公司 2025 年第二次临时股东大会 会议材料 2025 年 11 月 11 日 江苏硕世生物科技股份有限公司 2025 年第二次临时股东大会会议材料 江苏硕世生物科技股份有限公司 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东大会规则》以及《江苏硕世生物科技股份有限公司章程》《江苏硕世 生物科技股份有限公司股东大会议事规则》等相关规定，特制定 2025 年第二次 临时股东大会须知。 一、为保证本次大会的严肃性和正常秩序，切实维护与会股东（或股东代理 人）的合法权益，除出席会议的股东（或股东代理人）、公司董事、监事、高级 管理人员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他无关人员进 入会场。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示证券账户卡、身份证明文件或营业执照复印件（ ...

Core Points - The mid-term dividends from 20 companies, including Beijing-Shanghai High-Speed Railway Co., Ltd., Guotai Junan Securities Co., Ltd., and State Power Development Co., Ltd., will exceed 9 billion yuan from October 27 to October 31 [1] - As of October 24, 320 companies in the Shanghai market have distributed over 278 billion yuan in mid-term dividends, with an additional 90 companies expected to distribute over 280 billion yuan [1][2] - The total mid-term dividend amount for 414 companies has reached over 560 billion yuan, setting a historical high [1] Company-Specific Information - Major dividend payers include China Mobile and China Telecom, with cash distributions of 54.1 billion yuan and 16.6 billion yuan, respectively, while the "Big Three" oil companies have collectively distributed approximately 82.5 billion yuan [2] - Companies like Xiamen Gibit Network Technology Co., Ltd. and Jiangsu Shuoshi Biotechnology Co., Ltd. have reported per-share dividends exceeding 2 yuan, with Gibit reaching 6.6 yuan per share [2] Dividend Yield Insights - The dividend yield for 290 companies in the Shanghai market exceeds 3%, with 81 companies yielding over 5% [3] - Among the 320 companies that have implemented mid-term dividends, the average yield is 2.53%, with 102 companies exceeding 3% and 40 companies surpassing 5% [3]

Group 1 - The company has decided to change its registered capital and abolish the supervisory board, transferring its powers to the audit committee under the board of directors, which is in compliance with relevant laws and regulations [1][3] - The supervisory board unanimously agreed to the proposal, which aims to improve the corporate governance structure and better meet the company's operational needs [1][2] - The specific details of the changes were disclosed on the Shanghai Stock Exchange website [1] Group 2 - The company held its 13th meeting of the third board of directors on October 23, 2025, where it approved the appointment of Hu Yuanyuan as a member of the Strategy and ESG Committee [4][6] - The composition of the Strategy and ESG Committee after the appointment includes Fang Yongsheng (Chairman), Wang Guoqiang, Gao Guangxia, and Hu Yuanyuan [4] Group 3 - The company has scheduled its second extraordinary general meeting of shareholders for November 11, 2025, at 13:30 [7][8] - The meeting will be held at the company's conference room located at 837 Yaowang Avenue, Taizhou, Jiangsu Province [8] Group 4 - The company plans to conduct charitable donations in 2025, with a total amount not exceeding RMB 1.5 million, aimed at fulfilling its social responsibilities [27][28] - The donations will include cash and physical assets, and the management is authorized to handle all related matters [28][29] Group 5 - The company appointed Tu Xiaobao as the vice president, effective from the date of the board's approval until the end of the current board's term [31][32] - Tu Xiaobao has extensive experience in the company and meets the qualifications required for the position [31][33]

Core Points - The company has announced changes in its registered capital and governance structure, including the cancellation of the supervisory board and amendments to its articles of association [7][8] - The company completed a share buyback program, resulting in a reduction of registered capital due to the cancellation of 1.949918 million shares [7] - Following a capital reserve conversion, the company's total share capital increased from 56.670082 million shares to 83.871721 million shares, with corresponding registered capital rising from RMB 56.670082 million to RMB 83.871721 million [7] Financial Data - The financial statements for the third quarter are unaudited, and the company has confirmed the accuracy and completeness of the financial information presented [3][4] - The company has not reported any non-recurring gains or losses for the current period [4] - The company has not experienced significant changes in major accounting data or financial indicators [5] Shareholder Information - The company has provided details on the total number of shareholders and the status of major shareholders, although specific figures are not disclosed in the announcement [6] Governance Changes - The company will no longer have a supervisory board, with the audit committee of the board taking over its responsibilities [8] - The company plans to comprehensively revise its articles of association and related governance documents to reflect these changes [8]

Group 1 - The core point of the article indicates that Shuoshi Biotechnology (688399.SH) experienced a decline in revenue and net profit for the first three quarters of 2025, with revenue at 258 million yuan, a year-on-year decrease of 3.95% [1] - The net profit attributable to shareholders of the listed company was 3.1517 million yuan, reflecting a significant year-on-year decline of 88.38% [1] - The basic earnings per share for the company stood at 0.04 yuan [1]

Group 1 - The core viewpoint of the article highlights the financial performance of Shuoshi Biotechnology in Q3 2025, showing a decline in revenue and net profit compared to the previous year [1] - The company's revenue for the first three quarters of 2025 is approximately 258 million yuan, representing a year-on-year decrease of 3.95% [1] - The net profit attributable to shareholders is around 3.15 million yuan, reflecting a significant year-on-year decline of 88.38% [1] - Basic earnings per share are reported at 0.04 yuan, which is a decrease of 87.1% year-on-year [1] Group 2 - As of the report, the market capitalization of Shuoshi Biotechnology stands at 6.5 billion yuan [2] - The article also discusses the broader context of the biopharmaceutical market in China, noting that this year, overseas licensing has generated sales of 80 billion US dollars [2] - There is a contrast drawn between the hot secondary market for biopharmaceuticals and the cooling fundraising environment in the primary market [2]

Group 1 - The core point of the article is the appointment of Mr. Tu Xiaobao as the Vice President of Shuoshi Biotechnology, which was decided by the board of directors after a nomination process [1] - For the fiscal year 2024, Shuoshi Biotechnology's revenue composition is 94.78% from the in vitro diagnostic industry and 5.22% from other businesses [1] Group 2 - As of the report, Shuoshi Biotechnology has a market capitalization of 6.5 billion yuan [2] - The Chinese innovative drug sector has generated 80 billion dollars in overseas licensing deals this year, indicating a hot secondary market in biomedicine [2]

招商证券股份有限公司关于 江苏硕世生物科技股份有限公司 单位：万元 使用闲置募集资金进行现金管理的核查意见 招商证券股份有限公司（以下简称"保荐机构"、"招商证券"）作为江苏硕世生物 科技股份有限公司（以下简称"硕世生物"、"公司"、"发行人"）首次公开发行股票并 在科创板上市的保荐机构，根据《上海证券交易所科创板股票上市规则》《上市公司 募集资金监管规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》等法律、行政法规、部门规章及业务规则，对公司拟使用闲置募集资金进行现 金管理的事项进行了审慎核查，核查意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意江苏硕世生物科技股份有限公司首次公 开发行股票注册的批复》（证监许可[2019]2224 号）和上海证券交易所自律监管决定 书[2019]267 号核准同意，公司首次公开发行人民币普通股 1,466 万股，发行价格 46.78 元/股，新股发行募集资金总额为 68,579.48 万元，扣除发行费用 7,286.12 万元后，募 集资金净额为 61,293.36 万元，上述募集资金已经全部到位，并由立信会计师事务所 （特殊 ...

第一条 为进一步规范江苏硕世生物科技股份有限公司（以下简称"公司"）董事、 高级管理人员的薪酬管理，建立科学有效的激励与约束机制，保证公司董 事有效地履行其职责和义务，有效调动公司高级管理人员的工作积极性， 提高公司的经营管理效率，进一步促进公司稳定持续发展，根据《中华人 民共和国公司法》《上海证券交易所科创板股票上市规则》及《江苏硕世 生物科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定， 结合公司实际情况，制定本制度。 第二条 本制度适用于以下人员： 江苏硕世生物科技股份有限公司 董事、高级管理人员薪酬管理制度 第一章 总则 （一）董事会成员：包括非独立董事、独立董事。 （二）高级管理人员：包括公司总经理、副总经理、董事会秘书、财务负 责人及《公司章程》认定的其他人员。 第三条 公司薪酬制度遵循以下原则： （一）总体薪酬水平与公司经营规模、经营业绩相匹配原则； （二）责、权、利相结合的原则，总体薪酬水平与承担的管理责任、权限 相对应； （三）与公司长远发展相结合的原则，总体薪酬水平与公司持续健康发展 的目标相符； （四）激励与约束并重原则，总体薪酬水平与考核、奖惩、激励机制挂钩； （五）公开、 ...